Ongoing exploration to advance the promise of mRNA science
At Moderna, we are continually striving to push boundaries and explore new frontiers of mRNA science to help patients and impact lives.
We are fond of the expression, “We don’t know what we don’t know.” Using mRNA as a drug opens up a breadth of opportunities to treat and prevent disease. While we’ve made great strides to date, we believe we’ve only started to scratch the surface of the potential opportunities mRNA holds as a new class of medicines.
New Venture Labs is our internal incubator for ongoing exploration. The New Venture Labs team is focused on blue-sky research. Their thinking is not constrained by the current applications of our mRNA platform. Rather, they investigate new directions and applications for our platform, driven by curiosity and fueled by the possibilities and potential of one basic premise: what if mRNA could be a drug?
Ideas originally generated by New Venture Labs have led to the formation of our existing ventures. The pioneering work of the New Venture Labs team also resulted in our collaboration with Vertex to pursue mRNA therapies for cystic fibrosis.
New Venture Labs has enabled Moderna to remain a cutting-edge pioneer in the field of mRNA science, and has ensured that we maintain the spirit of innovation and inventiveness that has defined our company since its inception and propelled our success to date.